Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804
- PMID: 19496616
- DOI: 10.1021/bi900655f
Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804
Abstract
PH-797804 is a diarylpyridinone inhibitor of p38alpha mitogen-activated protein (MAP) kinase derived from a racemic mixture as the more potent atropisomer (aS), first proposed by molecular modeling and subsequently confirmed by experiments. On the basis of structural comparison with a different biaryl pyrazole template and supported by dozens of high-resolution crystal structures of p38alpha inhibitor complexes, PH-797804 is predicted to possess a high level of specificity across the broad human kinase genome. We used a structural bioinformatics approach to identify two selectivity elements encoded by the TXXXG sequence motif on the p38alpha kinase hinge: (i) Thr106 that serves as the gatekeeper to the buried hydrophobic pocket occupied by 2,4-difluorophenyl of PH-797804 and (ii) the bidentate hydrogen bonds formed by the pyridinone moiety with the kinase hinge requiring an induced 180 degrees rotation of the Met109-Gly110 peptide bond. The peptide flip occurs in p38alpha kinase due to the critical glycine residue marked by its conformational flexibility. Kinome-wide sequence mining revealed rare presentation of the selectivity motif. Corroboratively, PH-797804 exhibited exceptionally high specificity against MAP kinases and the related kinases. No cross-reactivity was observed in large panels of kinase screens (selectivity ratio of >500-fold). In cellular assays, PH-797804 demonstrated superior potency and selectivity consistent with the biochemical measurements. PH-797804 has met safety criteria in human phase I studies and is under clinical development for several inflammatory conditions. Understanding the rationale for selectivity at the molecular level helps elucidate the biological function and design of specific p38alpha kinase inhibitors.
Similar articles
-
Discovery and characterization of atropisomer PH-797804, a p38 MAP kinase inhibitor, as a clinical drug candidate.ChemMedChem. 2012 Feb 6;7(2):273-80. doi: 10.1002/cmdc.201100439. Epub 2011 Dec 15. ChemMedChem. 2012. PMID: 22174080
-
Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.Acta Crystallogr D Biol Crystallogr. 2008 Jul;D64(Pt 7):705-10. doi: 10.1107/S0907444908010032. Epub 2008 Jun 18. Acta Crystallogr D Biol Crystallogr. 2008. PMID: 18566506
-
Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.J Am Chem Soc. 2009 Sep 23;131(37):13286-96. doi: 10.1021/ja902010p. J Am Chem Soc. 2009. PMID: 19572644
-
Novel strategies for inhibition of the p38 MAPK pathway.Trends Pharmacol Sci. 2007 Jun;28(6):286-95. doi: 10.1016/j.tips.2007.04.008. Epub 2007 May 7. Trends Pharmacol Sci. 2007. PMID: 17482683 Review.
-
The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography.Chembiochem. 2005 Mar;6(3):506-12. doi: 10.1002/cbic.200400188. Chembiochem. 2005. PMID: 15696598 Review.
Cited by
-
Atypical p38 Signaling, Activation, and Implications for Disease.Int J Mol Sci. 2021 Apr 17;22(8):4183. doi: 10.3390/ijms22084183. Int J Mol Sci. 2021. PMID: 33920735 Free PMC article. Review.
-
p38 Mitogen activated protein kinase (MAPK): a new therapeutic target for reducing the risk of adverse pregnancy outcomes.Expert Opin Ther Targets. 2016 Dec;20(12):1397-1412. doi: 10.1080/14728222.2016.1216980. Epub 2016 Aug 4. Expert Opin Ther Targets. 2016. PMID: 27459026 Free PMC article. Review.
-
p38α Mitogen-Activated Protein Kinase Is a Druggable Target in Pancreatic Adenocarcinoma.Front Oncol. 2019 Nov 26;9:1294. doi: 10.3389/fonc.2019.01294. eCollection 2019. Front Oncol. 2019. PMID: 31828036 Free PMC article.
-
Apoptosis Signal-regulating Kinase 1 (ASK1)-p38 Pathway-dependent Cytoplasmic Translocation of the Orphan Nuclear Receptor NR4A2 Is Required for Oxidative Stress-induced Necrosis.J Biol Chem. 2015 Apr 24;290(17):10791-803. doi: 10.1074/jbc.M114.623280. Epub 2015 Mar 9. J Biol Chem. 2015. PMID: 25752609 Free PMC article.
-
Inhibition of p38 MAPK in combination with ART reduces SIV-induced immune activation and provides additional protection from immune system deterioration.PLoS Pathog. 2018 Aug 30;14(8):e1007268. doi: 10.1371/journal.ppat.1007268. eCollection 2018 Aug. PLoS Pathog. 2018. PMID: 30161247 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous